Ascletis' announces promising results for ASC47 adipose-targeted THRβ
Ascletis Pharma has announced that results of its Phase I single ascending dose (SAD) study in Australia in subjects with elevated...
top of page
Browse by category
Search
Browse by tag
bottom of page